Home > Journals > Panminerva Medica > Past Issues > Panminerva Medica 2020 March;62(1) > Panminerva Medica 2020 March;62(1):26-37



Publishing options
To subscribe
Submit an article
Recommend to your librarian


Publication history
Cite this article as



Panminerva Medica 2020 March;62(1):26-37

DOI: 10.23736/S0031-0808.19.03768-6


language: English

Liver disease and heart failure

Michele CORREALE 1 , Lucia TRICARICO 2, Alessandra LEOPIZZI 2, Adriana MALLARDI 2, Pietro MAZZEO 2, Salvatore TUCCI 2, Davide GRAZIOLI 3, Matteo DI BIASE 4, Natale D. BRUNETTI 1, 2

1 Unit of Cardiology, Ospedali Riuniti University Hospital of Foggia, Foggia, Italy; 2 Department of Medical and Surgical Sciences, University of Foggia, Foggia, Italy; 3 Santa Maria della Scaletta Hospital, Imola, Bologna, Italy; 4 GSM, Santa Maria Hospital, Bari, Italy

INTRODUCTION: Several systemic conditions, inflammatory disease, infections and alcoholism, may affect both the heart and the liver. Common conditions, such as the non-alcoholic fatty liver disease (NAFLD), may increase the risk of cardiac dysfunction. Patients with acute decompensated HF (ADHF) may develop acute ischemic hepatitis and, chronic HF patients may develop congestive hepatopathy (CH).
EVIDENCE ACQUISITION: Laboratory anomalies of hepatic function may predict the outcome of patients with advanced HF and the evaluation of both cardiac and hepatic function is very important in the management of these patients. In clinically apparent ischemic hepatitis more than 90% of patients have some right-sided HF. There are systemic disorders characterized by the accumulation of metals or by metabolism defects that may affect primarily the liver but also the heart leading to symptomatic hypertrophic cardiomyopathy (HCM).
EVIDENCE SYNTHESIS: Abnormal LFTs indicate the mechanism of liver injury: liver congestion or liver ischemia. In AHF, it’s important an adequate evaluation of heart and liver function in order to choose the treatment in order to ensure stable hemodynamic as well as optimal liver function.
CONCLUSIONS: Measurements of LFTs should be recommended in the early phase of ADHF management. Physicians with interest in HF should be trained in the evaluation of LFTs. It’s very important for cardiologists to know the systemic diseases affecting both heart and liver and the first imaging or laboratory findings useful for a diagnosis. it is very important for internists, nephrologists, cardiologists, primary physicians and any physicians with interest in treating HF to recognize such signs and symptoms belong to rare diseases and liver diseases that could be mistaken for HF.

KEY WORDS: Heart failure; Liver disease; Review literature as topic

top of page